Cyril H. Benes

Cyril H. Benes

Auto-generated profile, based on publicly available information

Cyril H. Benes

Massachusetts General Hospital, Harvard Medical School, Boston, USA

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2018 in Cancer Discovery
Verified
Journal Article
Closed access
PDF file
SCSean Caenepeel
Sean Caenepeel
SBSean P. Brown
Sean P. Brown
BBBrian Belmontes
Brian Belmontes
GMGordon Moody
Gordon Moody
KKKathleen S. Keegan
Kathleen S. Keegan
PHPaul E. Hughes
Paul E. Hughes
The prosurvival BCL2 family member MCL1 is frequently dysregulated in cancer. To overcome the significant challenges associated with inhibition of MCL1 protein–protein interactions, we rigorously applied small-molecule conformational restriction, which culminated in the discovery of AMG 176, the first selective MCL1 inhibitor to be studied in humans. We demonstrate that MCL1 inhibition induces a rapid and committed step toward apoptosis in subsets of hematologic cancer cell lines, tumor xenograft models, and primary patient samples. With the use of a human MCL1 knock-in mouse, we demonstrate that MCL1 inhibition at active doses of AMG 176 is tolerated and correlates with clear pharmacodynamic effects, demonstrated by reductions in B cells, monocytes, and neutrophils. Furthermore, the combination of AMG 176 and venetoclax is synergistic in acute myeloid leukemia (AML) tumor models and in primary patient samples at tolerated doses. These results highlight the therapeutic promise of AMG 176 and the potential for combinations with other BH3 mimetics. Significance: AMG 176 is a potent, selective, and orally bioavailable MCL1 inhibitor that induces a rapid commitment to apoptosis in models of hematologic malignancies. The synergistic combination of AMG 176 and venetoclax demonstrates robust activity in models of AML at tolerated doses, highlighting the promise of BH3-mimetic combinations in hematologic cancers. See related commentary by Leber et al., p. 1511. This article is highlighted in the In This Issue feature, p. 1494

1 August 2019 in Cancer Discovery
Verified
Journal Article
Closed access
PDF file
LGLipika Goyal
Lipika Goyal
LSLei Shi
Lei Shi
LLLeah Y. Liu
Leah Y. Liu
FCFerran Fece de la Cruz
Ferran Fece de la Cruz
JLJochen K Lennerz
Jochen K Lennerz
NBNabeel Bardeesy
Nabeel Bardeesy
ATP-competitive fibroblast growth factor receptor (FGFR) kinase inhibitors, including BGJ398 and Debio 1347, show antitumor activity in patients with intrahepatic cholangiocarcinoma (ICC) harboring activating FGFR2 gene fusions. Unfortunately, acquired resistance develops and is often associated with the emergence of secondary FGFR2 kinase domain mutations. Here, we report that the irreversible pan-FGFR inhibitor TAS-120 demonstrated efficacy in 4 patients with FGFR2 fusion–positive ICC who developed resistance to BGJ398 or Debio 1347. Examination of serial biopsies, circulating tumor DNA (ctDNA), and patient-derived ICC cells revealed that TAS-120 was active against multiple FGFR2 mutations conferring resistance to BGJ398 or Debio 1347. Functional assessment and modeling the clonal outgrowth of individual resistance mutations from polyclonal cell pools mirrored the resistance profiles observed clinically for each inhibitor. Our findings suggest that strategic sequencing of FGFR inhibitors, guided by serial biopsy and ctDNA analysis, may prolong the duration of benefit from FGFR inhibition in patients with FGFR2 fusion–positive ICC. Significance: ATP-competitive FGFR inhibitors (BGJ398, Debio 1347) show efficacy in FGFR2-altered ICC; however, acquired FGFR2 kinase domain mutations cause drug resistance and tumor progression. We demonstrate that the irreversible FGFR inhibitor TAS-120 provides clinical benefit in patients with resistance to BGJ398 or Debio 1347 and overcomes several FGFR2 mutations in ICC models. This article is highlighted in the In This Issue feature, p. 983

28 June 2019 in Science
Verified
Journal Article
Closed access
PDF file
RBRémi Buisson
Rémi Buisson
ALAdam Langenbucher
Adam Langenbucher
DBDanae Bowen
Danae Bowen
EKEugene E. Kwan
Eugene E. Kwan
CBCyril H. Benes
Cyril H. Benes
MLMichael Lawrence
Michael Lawrence
APOBEC3A hairpin passenger hotspots: Genomic features are often examined at extremes to determine the impact of mutations. These genomic regions span from the trinucleotide context to megabases that underlie chromatin and chromosomal features. Examining mutational dynamics at the mesoscale, the intermediate span of the genome, Buisson et al. characterized the mutational dynamics of cancer (see the Perspective by Carter). They found that mutations caused by the APOBEC enzyme in DNA stem-loops, a mesoscale feature of the genome, could drive recurrent mutations. Many of these types of mutations have been identified as likely drivers of cancer. However, APOBEC-generated mutations outside of stem-loops were more likely to be cancer driver mutations, providing a genomic context for separating cancer driver from passenger mutations. Science , this issue p. eaaw2872 ; see also p. 1228

7 October 2021 in Cancer Cell
Verified
Journal Article
Open access
HHHaichuan Hu
Haichuan Hu
ZPZofia Piotrowska
Zofia Piotrowska
PHPatricia Hare
Patricia Hare
HCHuidong Chen
Huidong Chen
HMHillary E. Mulvey
Hillary E. Mulvey
JEJeffrey A. Engelman
Jeffrey A. Engelman
Cancer-associated fibroblasts (CAFs) are highly heterogeneous. With the lack of a comprehensive understanding on CAFs’ functional distinctions, it remains unclear how cancer treatments could be personalized based on CAFs in a patient’s tumor. We have established a living biobank of CAFs derived from biopsies of patients’ non-small lung cancer (NSCLC) that encompasses a broad molecular spectrum of CAFs in clinical NSCLC. By functionally interrogating CAFs heterogeneity using the same therapeutics received by patients, we identify three functional subtypes: 1) robustly protective of cancers and highly expressing HGF and FGF7, 2) moderately protective of cancers and highly expressing FGF7, and 3) those providing minimal protection. These functional differences among CAFs are governed by their intrinsic TGF-β signaling which suppresses HGF and FGF7 expression. This CAF functional classification correlates with patients’ clinical response to targeted therapies and also associates with the tumor immune microenvironment, therefore provides an avenue to guide personalized treatment.

1 January 2020 in Cancer Discovery
Verified
Journal Article
Open access
PDF file
CCCarlotta Costa
Carlotta Costa
YWYe Wang
Ye Wang
ALAmy Ly
Amy Ly
YHYasuyuki Hosono
Yasuyuki Hosono
EMEllen Murchie
Ellen Murchie
DJDejan Juric
Dejan Juric
The combination of CDK4/6 inhibitors with antiestrogen therapies significantly improves clinical outcomes in ER-positive advanced breast cancer. To identify mechanisms of acquired resistance, we analyzed serial biopsies and rapid autopsies from patients treated with the combination of the CDK4/6 inhibitor ribociclib with letrozole. This study revealed that some resistant tumors acquired RB loss, whereas other tumors lost PTEN expression at the time of progression. In breast cancer cells, ablation of PTEN, through increased AKT activation, was sufficient to promote resistance to CDK4/6 inhibition in vitro and in vivo. Mechanistically, PTEN loss resulted in exclusion of p27 from the nucleus, leading to increased activation of both CDK4 and CDK2. Because PTEN loss also causes resistance to PI3Kα inhibitors, currently approved in the post-CDK4/6 setting, these findings provide critical insight into how this single genetic event may cause clinical cross-resistance to multiple targeted therapies in the same patient, with implications for optimal treatment-sequencing strategies. Significance: Our analysis of serial biopsies uncovered RB and PTEN loss as mechanisms of acquired resistance to CDK4/6 inhibitors, utilized as first-line treatment for ER-positive advanced breast cancer. Importantly, these findings have near-term clinical relevance because PTEN loss also limits the efficacy of PI3Kα inhibitors currently approved in the post-CDK4/6 setting. This article is highlighted in the In This Issue feature, p. 1

15 January 2019 in Clinical Cancer Research
Verified
Journal Article
Closed access
PDF file
SMSandra Misale
Sandra Misale
JFJackson P. Fatherree
Jackson P. Fatherree
ECEliane Cortez
Eliane Cortez
CLChendi Li
Chendi Li
SBSamantha J Bilton
Samantha J Bilton
CBCyril H. Benes
Cyril H. Benes
Purpose: KRAS mutant lung cancers have been recalcitrant to treatments including those targeting the MAPK pathway. Covalent inhibitors of KRAS p.G12C allele allow for direct and specific inhibition of mutant KRAS in cancer cells. However, as for other targeted therapies, the therapeutic potential of these inhibitors can be impaired by intrinsic resistance mechanisms. Therefore, combination strategies are likely needed to improve efficacy. Experimental Design: To identify strategies to maximally leverage direct KRAS inhibition we defined the response of a panel of NSCLC models bearing the KRAS G12C activating mutation in vitro and in vivo. We used a second-generation KRAS G12C inhibitor, ARS1620 with improved bioavailability over the first generation. We analyzed KRAS downstream effectors signaling to identify mechanisms underlying differential response. To identify candidate combination strategies, we performed a high-throughput drug screening across 112 drugs in combination with ARS1620. We validated the top hits in vitro and in vivo including patient derived xenograft models. Results: Response to direct KRAS G12C inhibition was heterogeneous across models. Adaptive resistance mechanisms involving reactivation of MAPK pathway and failure to induce PI3K-AKT pathway inactivation were identified as likely resistance events. We identified several model-specific effective combinations as well as a broad sensitizing effect of PI3K-AKT-mTOR pathway inhibitors. The G12Ci+PI3Ki combination was effective in vitro and in vivo on models resistant to single agent ARS1620 including patient derived xenografts models. Conclusions: Our findings suggest that signaling adaptation can in some instances limit the efficacy of ARS1620 but combination with PI3K inhibitors can overcome this resistance.